恆智動科技股份有限公司
Update：2026/08/06
Industries
Main Industry
Health Care
Main Product/Service
PapiVax’s product pipeline focuses on therapeutic vaccines against HPV infection and related cancers (e.g. cervical, head‑and‑neck cancers), with several candidates such as PVX‑4, PVX‑7, and PVX‑8 already in clinical‑trial stages; the company also offers
Founded Year
2025
Unified Business No.
96819818
Status
Active
Number of Employees
0
Total Paid-in
Capital
610,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
PapiVax Biotech, Inc., founded in 2013 and headquartered in Taipei with a subsidiary in the United States, is a biotech company specializing in nucleic‑acid immunotherapy using proprietary DNA‑plasmid vector and delivery platforms — aiming to become a glo
